Early phase 1Enrolling by invitation
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures: For Use in Healthy Individuals Ages 18-65 Who Seek to Improve Their Health and Longevity Through Low-dose (Microdosed) GLP1 Receptor Agonists
- Sponsor
- AgelessRx (Industry)
- Enrolment
- 150 planned
- Conditions
- Longevity; Quality of Life; Mood; Inflammation; Immune Health; Pain Management; Weight Management; Alertness
- Interventions
- GLP-1; Placebo
- Ages
- adults, older adults
- Registry
- NCT07092605
From the registry
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Primary outcomes
- Change in self-reported pain levels in participants microdosing GLP1s
- Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s
- Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s
- Change in mood in participants microdosing GLP1s
In the news
Trevogrumab prevents muscle loss during semaglutide treatment in Phase 2 trial
In an MRI substudy of the COURAGE trial, trevogrumab reduced semaglutide-associated muscle loss by 70 percent during weight reduction.
Allergan Aesthetics examines skin aging hallmarks in patients on GLP-1 drugs
Allergan Aesthetics is combining aging hallmarks science with clinical data to assess skin changes in patients using weight-loss medications.